Effects of An ACP Programme for Older People With Early Dementia

Sponsor
Hong Kong Metropolitan University (Other)
Overall Status
Completed
CT.gov ID
NCT05240664
Collaborator
Chinese University of Hong Kong (Other)
60
6
2
7.7
10
1.3

Study Details

Study Description

Brief Summary

Advance care planning (ACP) has been widely advocated for persons with early stage dementia (PWEDs). This proposed study attempts to promote the uptake of ACP for this population and their family caregivers in the community and to examine the effects of an ACP programme "Have a Say" for this population. It is hypothesized that participants in the intervention group will be more engaged in ACP and their dyadic concordance on end-of-life care preference with their family caregivers will be significantly higher than that in the control group.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Have A Say Programme
  • Behavioral: Attention-control health talks
N/A

Detailed Description

This study aims to evaluate the effects of an advance care planning (ACP) programme "Have a Say" for persons with early stage dementia (PWEDs) and their family caregivers in the community. A randomized controlled trial with repeated blinded outcome assessment will be conducted to assess the effects of an ACP programme on dyads of PWEDs and their family caregivers recruited from elderly community centres. Individuals who have a clinical diagnosis of any form of dementia at the early stage or have a Global Deterioration Score (GDS) 3 or 4 will be eligible to this study. Participants in the experimental group will receive a 4-session ACP programme. It includes an educational component, guided reflection and ACP discussion through a series of group-based activity and dyadic discussion delivered by trained ACP facilitator and guided by an ACP booklet. Dyads of participants will be provided with information about the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. They will be supported to have an individualized ACP discussion. Individuals assigned to the control group will receive attention-control health talks. The primary study outcome is the ACP engagement level of PWEDs. Secondary outcome is the dyadic concordance on end-of-life care preference. Adverse outcomes such as depression and caregivers' burden will also be evaluated. Data collection will be conducted at baseline, immediately after, and one-month after the intervention.

Study Design

Study Type:
Interventional
Actual Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Dyads of participants recruited from all elderly community centres will be randomized at block size equals to 4 in 1:1 ratio into intervention group and control group.Dyads of participants recruited from all elderly community centres will be randomized at block size equals to 4 in 1:1 ratio into intervention group and control group.
Masking:
Single (Outcomes Assessor)
Masking Description:
Outcome assessors will be blinded to the group assignment and research question.
Primary Purpose:
Health Services Research
Official Title:
Effects of An Advance Care Planning Programme for Persons With Early Dementia And Their Family Caregivers in the Community
Actual Study Start Date :
Jan 9, 2021
Actual Primary Completion Date :
Aug 31, 2021
Actual Study Completion Date :
Aug 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: ACP intervention

It is a theory-driven ACP programme specifically designed for PWEDs or persons with MCI and their family caregivers. The intervention is underpinned by the Bandura's self-efficacy model.

Behavioral: Have A Say Programme
Each dyad of participants will receive a 4-session ACP programme, which consists of 2 group-based sessions and 2 dyadic sessions, one hour for each session. The group-based sessions are led by nurse which include didactic educational components, guided reflection, videos, and group sharing. Dyads of participants will be provided with information about ACP, the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. The dyadic sessions are facilitated by trained ACP facilitators and guided by an ACP booklet. Dyads of participants will be supported to have an individualized ACP discussion guided by an ACP booklet. By the end of the programme, each dyad of participants will be given an ACP booklet documenting the ACP process.

Placebo Comparator: Attention-control health talks

Dyads of participants in the control group will receive health talks. This is to differentiate the effect of the intervention from the effect of the extra time and attention given to the participants.

Behavioral: Attention-control health talks
Dyads of participants in the control group will receive 4-session health talks. One hour for each session, and once weekly. The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health, and healthy diet.

Outcome Measures

Primary Outcome Measures

  1. Change in advance care planning engagement [Outcome will be measured at baseline, immediately after intervention, and 1-month after]

    The validated 9-item Advance Care Planning (ACP) Engagement Survey will be used to measure the engagement of PWED in the ACP process. Each item is measured on a five-point Likert scale and average 5-point scores will be calculated. It is originated from a longer version of 82 items measuring factors affecting the process of ACP engagement, including knowledge, contemplation, self-efficacy, and readiness. This shorter version reported sound psychometric properties and able to detect change across a broad range of ACP behaviours and ACP domains, with Cronbach's alpha =0.84, cross-sectional correlations =0.85, and delta correlations =0.68. The Chinese version of the ACP Engagement Survey is validated and reported sound psychometrical properties. This scale is composed of self-efficacy subscale and readiness subscale. Higher score reflects a higher level of ACP engagement.

Secondary Outcome Measures

  1. Change in dyadic concordance of preference on end-of-life care [Outcome will be measured at baseline, immediately after intervention, and 1-month after]

    The Life-Support Preferences Questionnaire will be used to measure the congruence on end-of-life care preferences between each participant dyad. This questionnaire has been modified and validated in the local context. The modified Chinese version of the Life Support Preferences Questionnaire was simplified to assess preferences regarding (i) three kinds of life-sustaining treatments (cardiopulmonary resuscitation, mechanical ventilator and tube feeding) based on three options (want to attempt, refuse or uncertain) and (ii) care goals (comfort-oriented, prolongation of life at all costs or uncertain) regarding a hypothetical end-of-life scenario (terminally ill). This scenario is based on the local advance directive form. Each member of the participated dyad will complete this questionnaire individually simultaneously. Higher score reflects a higher level of dyadic concordance.

  2. change in depression [Outcome will be measured at baseline, immediately after intervention, and 1-month after]

    The Cornell Scale for Depression in Dementia will be used to measure the signs and symptoms of depression of PWEDs. It is a validated instrument for various severity levels of dementia patients. This is a 19-item instrument that uses information from interviews with family caregivers. The Chinese version of this instrument reported an expert content validity index as 0.92, and its concurrent validity with the Geriatric Depression Scale short form is 0.322 (p<0.001). Its Cronbach's alpha for internal consistency reliability is 0.84. Higher score reflects a higher level of depression.

  3. Change in caregivers' stress [Outcome will be measured at baseline, immediately after intervention, and 1-month after]

    The Zarit Caregiver Burden Interview (ZBI) will be used to measure the caregivers' stress. It has 12 items. The Cantonese short version of this instrument reported sound psychometric properties. Higher score reflects a higher level of caregivers' stress.

Eligibility Criteria

Criteria

Ages Eligible for Study:
55 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • being Chinese,

  • being a Cantonese speaker,

  • having a formal diagnosis of any form of dementia at the early stage, or having a Global Deterioration Scale score 3-4,

  • having a designated family caregiver in direct contact and willing to participate in this study.

Exclusion Criteria:
  • non-communicable,

  • mentally incompetent,

  • received an ACP intervention,

  • have previously signed an advance directive,

  • have other life-limiting chronic illnesses.

A family caregiver involved in primary responsibility for caring and care-related decisions for the PWED will also be recruited. Paid caregivers are to be excluded.

Contacts and Locations

Locations

Site City State Country Postal Code
1 HKSKH Lok Man Alice Kwok Integrated Service Centre Kowloon Hong Kong
2 Hong Kong Christian Service Kowloon Hong Kong
3 Hong Kong Sheng Kung Hui Chuk Yuen Canon Martin District Elderly Community Centre Kowloon Hong Kong
4 Yang Memorial Methodist Social Service Choi Hung Community Centre for Senior Citizens Kowloon Hong Kong
5 Jockey Club Centre for Positive Ageing Sha Tin Hong Kong
6 Yau On Lutheran Centre for the Elderly Tuen Mun Hong Kong

Sponsors and Collaborators

  • Hong Kong Metropolitan University
  • Chinese University of Hong Kong

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Ms Cheryl Yeung Chi Yan, Principal Investigator, Hong Kong Metropolitan University
ClinicalTrials.gov Identifier:
NCT05240664
Other Study ID Numbers:
  • CREC 2019.438
First Posted:
Feb 15, 2022
Last Update Posted:
Mar 2, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ms Cheryl Yeung Chi Yan, Principal Investigator, Hong Kong Metropolitan University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 2, 2022